Clinical Trial

PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma

Study acronym: FIL_PUMA
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, multicenter, phase II study, in elderly patients affected by Mantle cell lymphoma (MCL) defined as unfit/frail according to Simplified Geriatric Assessment (sGA) and previously untreated. Patients will receive a treatment with Pirtobrutinib monotherapy until tumor progression, unacceptable adverse event, or patient decision for interruption.
Trial Details
NCT Number NCT07207785
Lead Sponsor Fondazione Italiana Linfomi - ETS
Conditions Mantle Cell Lymphoma
Enrollment 56 participants
Start Date 2026-02-01
Primary Completion 2028-02-01 (estimated)
Study Completion 2030-02-01 (estimated)
Updated on ClinicalTrials.gov 2025-10-06